ArticleScience translational medicine2014
Modulation of HCV replication after combination antiretroviral therapy in HCV/HIV co-infected patients.
Article in Science translational medicine, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT00545558 (Antiretroviral Therapy and the Hepatitis C Virus), which is not on this map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Antiretroviral Therapy and the Hepatitis C Virus
Who cites it
15 citing papers in PubMed.
- Direct-Acting Antivirals Quickly Eradicate Hepatitis C Virus From the Liver in People With Human Immunodeficiency Virus but Do Not Fully Reverse Immune Activation.The Journal of infectious diseases · 2025Trial
- Immunologic Change over 72 Weeks Following Raltegravir- Versus Efavirenz-Based Therapy in HIV/HCV-Coinfected Individuals in Vietnam.AIDS research and human retroviruses · 2022Trial
- Improvement in Hepatic Fibrosis Biomarkers Associated With Chemokine Receptor Inactivation Through Mutation or Therapeutic Blockade.Clinical infectious diseases : an official publication of the Infectious Diseases Society of America · 2019Trial
- Predictors of Acute HCV Incidence in People with HIV: Insights from a Long-term Cohort Study.Journal of acquired immune deficiency syndromes (1999) · 2025Article
- Using Health Information Technology to Create Pathways for Hepatitis C Treatment and Cure in West Virginia.Perspectives in health information managemen · 2022Article
- Article
- HIV and the liver.Topics in antiviral medicine · 2019Article
- Article
- A changing paradigm: management and treatment of the HCV/HIV-co-infected patient.Hepatology international · 2018Review
- A nonalcoholic fatty liver disease cirrhosis model in gerbil: the dynamic relationship between hepatic lipid metabolism and cirrhosis.International journal of clinical and experimental pathology · 2018Article
- Mechanisms of liver disease in patients infected with HIV.BMJ open gastroenterology · 2017Review
- Virologic and immunologic aspects of HIV-hepatitis C virus coinfection.AIDS (London, England) · 2016Review
- Recombination among GB virus C (GBV-C) isolates in the United States.The Journal of general virology · 2016Article
- Human immunodeficiency virus and liver disease: An update.Hepatology (Baltimore, Md.) · 2015Article
- Infectious disease. HIV therapy good for HCV infection.Nature reviews. Gastroenterology & hepatology · 2014Article
Corrections and comments
- Commented on by
Authors and funding
11 authors.
Funding
Abstract
The hepatitis C virus (HCV) is an important contributor to morbidity and mortality in patients co-infected with HIV. Co-infection results in increased HCV replication and more rapid rates of liver disease progression. The effect of HIV combination antiretroviral therapy (cART) on HCV replication has not been studied in depth. To address this issue, we enrolled a small cohort of HCV/HIV co-infected patients into a cART initiation trial and used dynamic modeling combined with evaluation of immune responses and microarray profiles to determine how effective treatment of HIV affects HCV. Treatment with cART resulted in increased HCV replication and increased alanine aminotransferase (ALT) in a subset of patients. Subjects with evidence of hepatic injury (increased ALT) were more likely to have HCV-specific immune responses directed against HCV epitopes. Over time, HCV viral loads declined. Reproducible and biologically important gene expression changes occurred in co-infected patients who underwent successful cART. The effective suppression of HIV by cART initiated a cascade of early and late events in treated patients. Early events involving down-regulation of interferon-stimulated genes may have led to transiently increased viral replication and hepatic injury. At later time points, HCV viral load declined to levels comparable to those seen in the setting of HCV monoinfection. These findings support early antiretroviral therapy in those with HCV/HIV co-infection.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.